SCHEMBL3873641

SCHEMBL3873641

CC1(C)CCCN1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2058181 0.93
SCHEMBL11868831 0.81 TSHR (0.31)
SCHEMBL6626567 0.78
SCHEMBL9278566 0.77
SCHEMBL29108962 0.75
SCHEMBL15364669 0.75
SCHEMBL4079651 0.75 TSHR (0.31)
SCHEMBL9286726 0.73 BDKRB2 (0.30)
SCHEMBL21865016 0.73 BDKRB2 (0.34)
SCHEMBL4166487 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014037313-A1 USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2014-03-13 WO disclosed
US-7601748-B2 Anti-androgenic N-[ omega -[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines; treatment of prostate cancer, benign prostate hyperplasia, androgenetic alopecia, hirsutism or acne BAYER SCHERING PHARMA AG (DE) 2009-10-13 US disclosed
EP-1622894-B1 ANTITUMORAL ANTIANDROGENIC PYRROLIDINES BAYER SCHERING PHARMA AG (DE) 2009-01-14 EP disclosed
US-20070021481-A1 Anti-androgenic pyrrolidines with tumor-inhibiting action BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-01-25 US disclosed
US-7138421-B2 Anti-androgenic pyrrolidines with tumor-inhibiting action SCHRING AKTIENGESELLSCHAFT (DE) 2006-11-21 US disclosed
US-20050159468-A1 Anti-androgenic pyrrolidines with tumor-inhibiting action BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-07-21 US disclosed